Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians: a randomized double-blind crossover study.
Identifieur interne : 001788 ( PubMed/Corpus ); précédent : 001787; suivant : 001789Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians: a randomized double-blind crossover study.
Auteurs : H. Allain ; F. Le Coz ; F. Goulley ; F. Brunet-Bourgin ; Y. Loria ; D. Bentue-Ferrer ; R. Decombe ; J M Reymann ; P. Chaumet-Riffaud ; J M GandonSource :
- International journal of clinical pharmacology, therapy, and toxicology [ 0174-4879 ] ; 1991.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Behavior (drug effects), Bromocriptine (administration & dosage), Bromocriptine (adverse effects), Bromocriptine (therapeutic use), Delayed-Action Preparations, Double-Blind Method, Female, Humans, Levodopa (therapeutic use), Male, Middle Aged, Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Parkinson Disease (psychology).
- MESH :
- chemical , administration & dosage : Bromocriptine.
- chemical , adverse effects : Bromocriptine.
- drug effects : Behavior.
- drug therapy : Parkinson Disease.
- metabolism : Parkinson Disease.
- psychology : Parkinson Disease.
- chemical , therapeutic use : Bromocriptine, Levodopa.
- Adult, Aged, Aged, 80 and over, Delayed-Action Preparations, Double-Blind Method, Female, Humans, Male, Middle Aged.
Abstract
Parlodel-SRO is a newly developed slow-release formulation of bromocriptine, which prevents initial plasma peak--a known source of adverse events--and extends the half-life of the compound, an interesting feature for the management of motor symptoms in Parkinsonians. This study was designed to determine the best daily administration schedule for 30 mg Parlodel-SRO in 18 parkinsonians previously treated with levodopa and standard Bromocriptine (Br). The 30 mg dose was replaced from one day to the next, in a randomized, double-blind latin square design trial. Three consecutive 7-day courses were implemented, during which a total daily dose of 30 mg P-SRO was administered in one dose, two intakes (b.i.d.) and three intakes, (t.i.d.) respectively. The b.i.d. schedule produced the best improvement in UPDRS scores, especially as to postural stability, walking, bradykinesia; it also provided greater pharmacological stability throughout the assessment day. Adverse event analysis was not in favor of a single daily dose. It appeared that P-SRO administered in two 15 mg intakes (morning and evening) produces the best benefit-risk ratio in Parkinsonians who were already being treated with levodopa.
PubMed: 1743806
Links to Exploration step
pubmed:1743806Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians: a randomized double-blind crossover study.</title><author><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H" last="Allain">H. Allain</name><affiliation><nlm:affiliation>Department of Neurology and Neuropharmacology, University Hospital, Rennes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Le Coz, F" sort="Le Coz, F" uniqKey="Le Coz F" first="F" last="Le Coz">F. Le Coz</name></author><author><name sortKey="Goulley, F" sort="Goulley, F" uniqKey="Goulley F" first="F" last="Goulley">F. Goulley</name></author><author><name sortKey="Brunet Bourgin, F" sort="Brunet Bourgin, F" uniqKey="Brunet Bourgin F" first="F" last="Brunet-Bourgin">F. Brunet-Bourgin</name></author><author><name sortKey="Loria, Y" sort="Loria, Y" uniqKey="Loria Y" first="Y" last="Loria">Y. Loria</name></author><author><name sortKey="Bentue Ferrer, D" sort="Bentue Ferrer, D" uniqKey="Bentue Ferrer D" first="D" last="Bentue-Ferrer">D. Bentue-Ferrer</name></author><author><name sortKey="Decombe, R" sort="Decombe, R" uniqKey="Decombe R" first="R" last="Decombe">R. Decombe</name></author><author><name sortKey="Reymann, J M" sort="Reymann, J M" uniqKey="Reymann J" first="J M" last="Reymann">J M Reymann</name></author><author><name sortKey="Chaumet Riffaud, P" sort="Chaumet Riffaud, P" uniqKey="Chaumet Riffaud P" first="P" last="Chaumet-Riffaud">P. Chaumet-Riffaud</name></author><author><name sortKey="Gandon, J M" sort="Gandon, J M" uniqKey="Gandon J" first="J M" last="Gandon">J M Gandon</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1991">1991</date><idno type="RBID">pubmed:1743806</idno><idno type="pmid">1743806</idno><idno type="wicri:Area/PubMed/Corpus">001788</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001788</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians: a randomized double-blind crossover study.</title><author><name sortKey="Allain, H" sort="Allain, H" uniqKey="Allain H" first="H" last="Allain">H. Allain</name><affiliation><nlm:affiliation>Department of Neurology and Neuropharmacology, University Hospital, Rennes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Le Coz, F" sort="Le Coz, F" uniqKey="Le Coz F" first="F" last="Le Coz">F. Le Coz</name></author><author><name sortKey="Goulley, F" sort="Goulley, F" uniqKey="Goulley F" first="F" last="Goulley">F. Goulley</name></author><author><name sortKey="Brunet Bourgin, F" sort="Brunet Bourgin, F" uniqKey="Brunet Bourgin F" first="F" last="Brunet-Bourgin">F. Brunet-Bourgin</name></author><author><name sortKey="Loria, Y" sort="Loria, Y" uniqKey="Loria Y" first="Y" last="Loria">Y. Loria</name></author><author><name sortKey="Bentue Ferrer, D" sort="Bentue Ferrer, D" uniqKey="Bentue Ferrer D" first="D" last="Bentue-Ferrer">D. Bentue-Ferrer</name></author><author><name sortKey="Decombe, R" sort="Decombe, R" uniqKey="Decombe R" first="R" last="Decombe">R. Decombe</name></author><author><name sortKey="Reymann, J M" sort="Reymann, J M" uniqKey="Reymann J" first="J M" last="Reymann">J M Reymann</name></author><author><name sortKey="Chaumet Riffaud, P" sort="Chaumet Riffaud, P" uniqKey="Chaumet Riffaud P" first="P" last="Chaumet-Riffaud">P. Chaumet-Riffaud</name></author><author><name sortKey="Gandon, J M" sort="Gandon, J M" uniqKey="Gandon J" first="J M" last="Gandon">J M Gandon</name></author></analytic><series><title level="j">International journal of clinical pharmacology, therapy, and toxicology</title><idno type="ISSN">0174-4879</idno><imprint><date when="1991" type="published">1991</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Behavior (drug effects)</term><term>Bromocriptine (administration & dosage)</term><term>Bromocriptine (adverse effects)</term><term>Bromocriptine (therapeutic use)</term><term>Delayed-Action Preparations</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (metabolism)</term><term>Parkinson Disease (psychology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Bromocriptine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Bromocriptine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Behavior</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Bromocriptine</term><term>Levodopa</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Delayed-Action Preparations</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parlodel-SRO is a newly developed slow-release formulation of bromocriptine, which prevents initial plasma peak--a known source of adverse events--and extends the half-life of the compound, an interesting feature for the management of motor symptoms in Parkinsonians. This study was designed to determine the best daily administration schedule for 30 mg Parlodel-SRO in 18 parkinsonians previously treated with levodopa and standard Bromocriptine (Br). The 30 mg dose was replaced from one day to the next, in a randomized, double-blind latin square design trial. Three consecutive 7-day courses were implemented, during which a total daily dose of 30 mg P-SRO was administered in one dose, two intakes (b.i.d.) and three intakes, (t.i.d.) respectively. The b.i.d. schedule produced the best improvement in UPDRS scores, especially as to postural stability, walking, bradykinesia; it also provided greater pharmacological stability throughout the assessment day. Adverse event analysis was not in favor of a single daily dose. It appeared that P-SRO administered in two 15 mg intakes (morning and evening) produces the best benefit-risk ratio in Parkinsonians who were already being treated with levodopa.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1743806</PMID><DateCreated><Year>1992</Year><Month>01</Month><Day>14</Day></DateCreated><DateCompleted><Year>1992</Year><Month>01</Month><Day>14</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0174-4879</ISSN><JournalIssue CitedMedium="Print"><Volume>29</Volume><Issue>8</Issue><PubDate><Year>1991</Year><Month>Aug</Month></PubDate></JournalIssue><Title>International journal of clinical pharmacology, therapy, and toxicology</Title><ISOAbbreviation>Int J Clin Pharmacol Ther Toxicol</ISOAbbreviation></Journal><ArticleTitle>Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians: a randomized double-blind crossover study.</ArticleTitle><Pagination><MedlinePgn>314-22</MedlinePgn></Pagination><Abstract><AbstractText>Parlodel-SRO is a newly developed slow-release formulation of bromocriptine, which prevents initial plasma peak--a known source of adverse events--and extends the half-life of the compound, an interesting feature for the management of motor symptoms in Parkinsonians. This study was designed to determine the best daily administration schedule for 30 mg Parlodel-SRO in 18 parkinsonians previously treated with levodopa and standard Bromocriptine (Br). The 30 mg dose was replaced from one day to the next, in a randomized, double-blind latin square design trial. Three consecutive 7-day courses were implemented, during which a total daily dose of 30 mg P-SRO was administered in one dose, two intakes (b.i.d.) and three intakes, (t.i.d.) respectively. The b.i.d. schedule produced the best improvement in UPDRS scores, especially as to postural stability, walking, bradykinesia; it also provided greater pharmacological stability throughout the assessment day. Adverse event analysis was not in favor of a single daily dose. It appeared that P-SRO administered in two 15 mg intakes (morning and evening) produces the best benefit-risk ratio in Parkinsonians who were already being treated with levodopa.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Allain</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neuropharmacology, University Hospital, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Coz</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Goulley</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Brunet-Bourgin</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Loria</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Bentue-Ferrer</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Decombe</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Reymann</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Chaumet-Riffaud</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Gandon</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Int J Clin Pharmacol Ther Toxicol</MedlineTA><NlmUniqueID>8003415</NlmUniqueID><ISSNLinking>0174-4879</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003692">Delayed-Action Preparations</NameOfSubstance></Chemical><Chemical><RegistryNumber>3A64E3G5ZO</RegistryNumber><NameOfSubstance UI="D001971">Bromocriptine</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001519" MajorTopicYN="N">Behavior</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001971" MajorTopicYN="N">Bromocriptine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003692" MajorTopicYN="N">Delayed-Action Preparations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1743806</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001788 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001788 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:1743806
|texte= Comparison of three regimens of Parlodel-SRO in levodopa-treated parkinsonians: a randomized double-blind crossover study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:1743806" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |